Viatris (VTRS) fundamentals: P/E, valuation, undervalued?
Viatris · Health Care · ref. ETF XLV · price $16.89
In short — Viatris trades at —× earnings (P/E), 6.3× forward, with a net margin of -2.8 % and revenue growth of +5 %. Read: Not (yet) profitable (valued on growth, not earnings).
Is Viatris stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$16.89+62.2% over range
Aug 28, 25low $9.49 · high $17.86Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
67% recommend buying · 3 analysts
Valuation : Not (yet) profitable — valued on growth, not earnings
Valuation
—
P/E (price/earnings)
6.3
Forward P/E
—
PEG
1.3
Price/book (P/B)
$19.4B
Market cap
-0.37
EPS
Profitability & growth
-2.8 %
Net margin
+5 %
Revenue growth
—
Earnings growth
$13.6B
Total debt
Viatris income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $16.3B | $2.1B | 12.8 % |
| 2023 | $15.4B | $55M | 0.4 % |
| 2024 | $14.7B | $-634M | -4.3 % |
| 2025 | $14.3B | $-3.5B | -24.6 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Viatris's P/E and is the stock undervalued? What's a good P/E?
Viatris's P/E is — (forward 6.3). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Not (yet) profitable".
Is Viatris profitable?
Viatris has a net margin of -2.8 % (EPS -0.37). The company is not (yet) profitable.
Is VTRS stock expensive?
Our read: "Not (yet) profitable" — valued on growth, not earnings. Cross-check with growth and sector.
💬 A question about Viatris? The JPI assistant answers using our backtest data.